Patents by Inventor Patricia Perez de Cogram

Patricia Perez de Cogram has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10548892
    Abstract: Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat symptoms of Autism Spectrum Disorders and Neurodevelopmental Disorders as well as manufacture of medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: February 4, 2020
    Assignee: NEUREN PHARMACEUTICALS LIMITED
    Inventors: Lawrence Irwin Glass, Michael John Bickerdike, Michael Frederick Snape, Patricia Perez De Cogram
  • Publication number: 20180140601
    Abstract: Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat symptoms of Autism Spectrum Disorders and Neurodevelopmental Disorders as well as manufacture of medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 24, 2018
    Applicant: Neuren Pharmaceuticals Limited
    Inventors: Lawrence Irwin Glass, Michael John Bickerdike, Michael Frederick Snape, Patricia Perez De Cogram
  • Patent number: 9867823
    Abstract: Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat Autism Spectrum Disorders and Neurodevelopmental Disorders as well as manufacture of medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: January 16, 2018
    Assignee: NEUREN PHARMACEUTICALS LIMITED
    Inventors: Lawrence Irwin Glass, Michael John Bickerdike, Michael Frederick Snape, Patricia Perez De Cogram
  • Publication number: 20170020869
    Abstract: Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat Autism Spectrum Disorders and Neurodevelopmental Disorders as well as manufacture of medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.
    Type: Application
    Filed: January 22, 2016
    Publication date: January 26, 2017
    Applicant: Neuren Pharmaceuticals Limited
    Inventors: Lawrence Irwin Glass, Michael John Bickerdike, Michael Frederick Snape, Patricia Perez De Cogram
  • Publication number: 20150224164
    Abstract: This invention provides compounds, compositions and methods for treating Autism Spectrum Disorders (ASD) using glycyl-2-methylprolyl-glutamic acid (G-2-MePE) and analogs thereof. Autism Spectrum Disorders include Autism, Autistic Disorder, Asperger Syndrome, Childhood Disintegrative Disorder, Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS), Fragile X Syndrome, and Rett Syndrome. Compositions containing compounds include water-soluble formulations, water-in-oil micro-emulsions, water-in-oil coarse emulsions, water-in-oil liquid crystals, nanocapsules, tablets, and orally administered gels. The compounds and compositions of this invention can be administered intravenously, intraventricularly, parenterally, or orally, and can be effective in treating neurodegeneration, promoting neurological function, treating seizure activity and other symptoms of ASD, and can prolong life in animals including human beings having Autism Spectrum Disorders.
    Type: Application
    Filed: February 9, 2015
    Publication date: August 13, 2015
    Inventors: Lawrence Irwin Glass, Michael John Bickerdike, Michael Frederick Snape, Patricia Perez de Cogram